Overall, these findings identify GA-NPs@DCV as an effective personalized nanovaccine that can simultaneously deliver tumor antigens and the Stat3 inhibitor GA to the tumor microenvironment to exert potent antitumor effects, providing a promising immunotherapeutic strategy for ovarian cancer. Here, STAT3 is linked to ovarian cancer.